Abstract 77P
Background
Neuroblastoma (NBL) is the most common and aggressive cancer in infants, and there are no robust predictive nomograms for NBL. In this study, a database from the Therapeutically Applicable Research to Generate Effective Treatments was applied to develop and validate a prognostic nomogram for the prediction of individual 5-year overall survival (OS) probability in patients with NBL.
Methods
A total of 729 eligible NBL patients with their clinicopathological factors and biological characteristics from the database were assigned to either the training cohort (n = 511) or the validation cohort (n = 218). Independent predictors were identified by fitting the Cox model with lasso penalty and then were assembled into a nomogram to predict survival. The model was developed for predicting individual 5-year OS probability and was then internally and externally validated, calibrated and compared in each cohort.
Results
Four independent prognostic factors (International NBL Staging System stage, ploidy, histology and Children’s Oncology Group risk group) were discriminated and achieved favourable prediction efficacy following the lasso model. The prognostic nomogram incorporated those factors that performed well in the training and validation cohorts with OS (HR = 0.36, 95% CI: 0.27-0.48, P < 0.0 001; HR = 0.54, 95% CI: 0.34-0.86, P = 0.0 086; respectively) and recurrence-free survival (HR = 0.52, 95% CI: 0.40-0.67, P < 0.0 001; HR = 0.66, 95% CI: 0.44-0.99, P = 0.044; respectively).
Conclusions
The robust prognostic nomogram with four independent prognostic factors can accurately and diversely predict OS and recurrence-free survival in NBL patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract